Overall, the magnitude and consistency of the treatment effect observed in these indirect comparisons strongly support that treatment with leniolisib reduces the rate of respiratory infections and high levels of serum IgM in people with APDS, compared with the current standard of care. Here, CD40LG is linked to respiratory tract infectious disorder.